How US FDA's Assumptions Impacted Generic Program Fees

FDA decided against trying to predict upcoming approvals as part of FY 2019 GDUFA program fee calculations, but other adjustments likely increased fee significantly.

FDAEntrance_1200x675

The US FDA decided not to adjust the FY 2019 GDUFA program fee to account for firms that could jump tiers in the middle of the fiscal year, potentially saving ANDA owners some money.

FDA also changed a variable that was used in its calculations, another example of FDA learning how to use its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership